Exelixis (EXEL) – Research Analysts’ Weekly Ratings Changes

Exelixis (NASDAQ: EXEL) recently received a number of ratings updates from brokerages and research firms:

• 10/4/2024 – Exelixis had its price target raised by analysts at Royal Bank of Canada from $27.00 to $30.00. They now have an “outperform” rating on the stock.
• 9/26/2024 – Exelixis had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
• 9/20/2024 – Exelixis had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $29.00 price target on the stock.
• 9/19/2024 – Exelixis is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $30.00 price target on the stock.
• 9/18/2024 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.

Exelixis Stock Performance

Shares of EXEL stock traded down $0.20 during trading hours on Thursday, hitting $25.23. The company had a trading volume of 85,269 shares, compared to its average volume of 1,990,133. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $27.83. The firm has a market capitalization of $7.65 billion, a price-to-earnings ratio of 39.42, a PEG ratio of 0.56 and a beta of 0.54. The firm’s fifty day moving average is $26.06 and its 200 day moving average is $23.64.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. The business had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. On average, sell-side analysts expect that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 20,883 shares of Exelixis stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $27.06, for a total value of $565,093.98. Following the completion of the sale, the executive vice president now directly owns 500,107 shares in the company, valued at approximately $13,532,895.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 327,858 shares of company stock worth $8,640,129. Insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Institutional investors have recently made changes to their positions in the company. LSV Asset Management raised its position in Exelixis by 1,651.4% during the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after purchasing an additional 2,616,278 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Exelixis by 45.3% during the 2nd quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock worth $2,031,000 after purchasing an additional 28,126 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Exelixis by 1.6% during the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Exelixis by 948.3% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after purchasing an additional 2,220,150 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Exelixis by 155.8% during the 1st quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company’s stock worth $2,374,000 after purchasing an additional 60,925 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.